International Journal of Endocrinology / 2014 / Article / Tab 1

Review Article

Inflammatory Response in Islet Transplantation

Table 1

Anti-inflammatory agents in clinical allogeneic islet cell transplantation.

Publication yearPt numberAnti-inflammatory agentsDose of anti-inflammatory agentsInduction therapyMaintenance therapyMajor outcomesReferences

20058Etanercept50 mg i.v. pretransplant and 25 mg s.c. on days 3, 7, and 10rATG
Daclizumab
Sirolimus
Tacrolimus
MMF
100% II after single infusion[130]

20058Infliximab5 mg/kg i.v. pretransplantDaclizumabSirolimus
Tacrolimus
7/8 recipients achieved II[131]

20087Infliximab or Etanercept5 mg/kg i.v. pretransplant or 50 mg i.v. pretransplant and 25 mg s.c. twice weekly for 2 weeksDaclizumabSirolimus
Tacrolimus
(Low-dose steroids for 3 pts)
6/7 recipients achieved II[146]

20083Etanercept50 mg i.v. pretransplant and 25 mg s.c. twice weekly for 2 weeksAlemtuzumabSirolimus
Tacrolimus
MMF
2/3 recipients achieved II[147]

20086Etanercept50 mg i.v. pretransplant and 24 mg s.c. on days 3, 7, and 10rATG (for first transplant)
Daclizumab (for 2nd transplant)
Cyclosporine
Everolimus
5/6 recipients achieved II[148]

20086Etanercept50 mg i.v. pretransplant and 24 mg s.c. on days 3, 7 and 10DaclizumabSirolimus
Tacrolimus
6/6 recipients achieved II[149]

20113Etanercept and anakinra50 mg i.v. pretransplant and 25 mg s.c. on days 3, 6, and 10 and 100 mg i.v. pretransplant and 100 mg s.c. for 7 days after transplantrATGTacrolimus
MMF
3/3 recipients achieved II[135]

2012*22Anti-TNF-αNAT-cell depletion protocolNA50% of recipients kept II for 5 years[132]

i.v. indicates intravenous injection; s.c., subcutaneous injection; rATG, rabbit antithymocyte globulin; MMF, mycophenolate mofetil; II, insulin independence; TNF, tumor necrosis factor.
*Based on collaborative islet transplant registry, collecting data from multiple centers.